Sensitivity did not seem to be related to PIK3CA mutational status or ER status (Fig 2), in agreement with a previous study reporting a lack of correlation of everolimus sensitivity to PIK3CA mutation in breast cancer [28]. Here, PIK3CA is linked to breast cancer.